Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: JorA treated bladder cancer cells for transcriptome

PROVIDER: PRJNA891952 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21968787_1.fastq.gz	Fastqsanger.gz
	SRR21968787_2.fastq.gz	Fastqsanger.gz
	SRR21968788_1.fastq.gz	Fastqsanger.gz
	SRR21968788_2.fastq.gz	Fastqsanger.gz
	SRR21968789_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Homo sapiens

Project description:Nodosin treated bladder cancer cells for transcriptome sequencing

| PRJNA826421 | ENA

Homo sapiens

Project description:Nodosin treated bladder cancer cells for transcriptome sequencing

| PRJNA826422 | ENA

Project description:Nodosin treated bladder cancer cells for transcriptome sequencing

| PRJNA824669 | ENA

Project description:Talaroconvolutin-A treated bladder cancer cells for transcriptome sequencing

| PRJNA895115 | ENA

Genome-wide transcriptome analysis of PAK4 inhibition/knockdown in human bladder cancer cell line VMCUB1

Project description:Using multi-omic analyses, we identified PAK4 (P21 (RAC1) Activated Kinase 4) amplification and overexpression of Kinase PAK4 in a subset of bladder cancers. We confirmed the role of PAK4 in bladder cancer cell proliferation and invasion by in vitro experiments. Furthermore, our studies showed that PAK4 inhibitor is effective in curtailing bladder cancer cell growth. In order to understand the effect of PAK4 inhibition and knockdown on bladder cancer transcriptome, we performed RNA-sequencing of PAK4 siRNA transfected and PAK4 inhibitor (PF-3758309) treated bladder cancer cells (VM-CUB1). Analyses led to identification of direct targets of PAK4 in bladder cancer and associated pathways.

2020-04-20 | GSE130455 | GEO

Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles involves in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer

Project description:Proteomic characterization of extracellular vesicles derived from bladder cancer cells overexpressing GSTO1 and treated with cisplatin.

2025-02-20 | PXD049720 | JPOST Repository

Transcriptome analysis reveals anti-cancer effects of Isorhapontigenin (ISO) on human high invasive bladder cancer cells

Project description:Bladder cancer, the most common malignancy of the urinary tract, has a poor overall survival rate if the tumor becomes muscle invasive. The discovery and evaluation of new alternative medications targeting high-grade muscle invasive bladder cancer (MIBC) are of tremendous importance in reducing bladder cancer mortality. Isorhapontigenin (ISO), a stilbene derivative from Chinese herb Gnetum cleistostachyum, exhibits a strong anti-cancer effect on MIBCs. Here, we report the whole transcriptome profiling of ISO-treated human bladder cancer T24 cells. A total of 1047 differentially expressed genes (DEGs) were identified, including 596 downregulated and 451 upregulated genes. Functional annotation and pathway analysis revealed that ISO treatment induced massive changes in gene expression associated with cell movement, migration, invasion, metabolism, proliferation, and angiogenesis. Additionally, ISO treatment activated genes involved in the inflammatory response but repressed genes involved in hypoxia signaling, glycolysis, the actin cytoskeleton, and the tumor microenvironment. In summary, our whole transcriptome analysis demonstrated a shifted metabolism and altered actin cytoskeleton in ISO treated T24 cells, which subsequently contribute to tumor microenvironment remodeling that suppresses tumor growth and progression.

2024-02-14 | GSE252406 | GEO

Lactylome and proteomics analyses of bladder cancer

Project description:Lactylome and proteomics analyses in bladder cancer cells treated with EPI

2025-06-10 | PXD062720 | Pride

Project description:mannose treated in bladder cancer

| PRJNA1235444 | ENA

Homo sapiens

Project description:Bladder cancer cells

| PRJNA87773 | ENA